Accenture has launched a new business service, known as Accelerated R&D Services, to accelerate drug development from discovery to approval to market.
Focused on delivering streamlined and integrated research and development (R&D) functions, the service will help pharmaceutical companies bring new medications to patients at a faster pace.
The company has planned to invest over $200m in delivering this service which results in driving efficient and effective development of pharmaceutical products for clients.
The company's R&D services will use all the capabilities of cloud, mobility and analytics to deliver integrated functions and market launch predicated on delivering better patient outcomes.
Accelerated R&D Services helps life sciences companies bring drugs to market faster, at less cost and with reduced execution risks using a pay-for-performance business model for business process outsourcing.
To support the strategic R&D initiatives, the company is operating with a leading pharmaceutical company to build a clinical data aggregation and exchange platform.
The company is also currently working with associations such as CDISC and Transcelerate BioPharma to advance industry-wide clinical data standards, streamline research processes and encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies.
